Multiple Myeloma
January 2019 Vol 10, No 1 | January 11, 2019
Navigating patients through the complexities of multiple myeloma can be very challenging – yet very rewarding.
June 2018 Vol 9, No 6 | June 12, 2018
A maintenance regimen of lenalidomide (Revli-mid) and elotuzumab (Empliciti) after autologous stem cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
2018 Third Annual Oncology Guide to New FDA Approvals | June 6, 2018
On February 22, 2017, the US Food and Drug Administration (FDA) approved lenalidomide (Revlimid; Celgene), an oral IMiD, for maintenance therapy after autologous HSCT in patients with multiple myeloma.
April 2018 Vol 9, No 4 | April 10, 2018
Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
Recent advances in the treatment of multiple myeloma have dramatically altered the trajectory of disease, as providers now have several efficacious agents in various drug classes at their disposal.
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
Despite major and continuing treatment interventions, myeloma remains incurable for most patients, and relapse is an expected part of the disease course. At the National Comprehensive Cancer Network 12th Annual Congress: Hematologic Malignancies, Natalie S. Callander, MD, outlined issues in the management of relapsed/refractory multiple myeloma (RRMM).
Best Practices in Hematologic Malignancies – December 2017 Vol 8 | December 15, 2017
Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a proteasome inhibitor, was approved by the FDA on June 16, 2017.
May 2016 Vol 7, No 4 | April 29, 2016
The following are a selection of key clinical trials that are currently recruiting patients for inclusion in investigations of new therapies and new regimens of available therapies for patients with multiple myeloma. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials.
March 2016 Vol 7, No 2 | March 4, 2016
A report on the second most common blood cancer and the progress being made in raising awareness of this disease.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512